Full-Time

Senior Supplier Engineer

Posted on 9/29/2025

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Blacksburg, VA, USA

In Person

Category
Operations & Logistics (2)
,
Required Skills
GD&T
SAP Products
Requirements
  • Excellent verbal and written communication skills, with the ability to deliver presentations and influence cross-functional teams
  • Ability to motivate suppliers and lead cross-functional teams to resolve complex technical and process issues
  • Excellent analytical skills and ability to translate data into meaningful strategic messaging
  • Demonstrable knowledge of a wide range of manufacturing processes including machining, metal fabrication, plastics molding, electronics, and contract manufacturing, with understanding of key input variables for quality, cost, and capacity
  • Proficient in project management, problem-solving, and structured root cause analysis techniques
  • Ability to read, interpret, and communicate detailed mechanical drawings including GD&T
  • Strong computer skills including proficiency in Microsoft Office suite and ERP systems (preferably SAP)
  • Minimum 8 years of experience in relevant field and a bachelor's degree in engineering, or equivalent combination of education and experience
  • Travel ~10% to both domestic and international suppliers and Intuitive facilities
Responsibilities
  • Develop and execute supply chain strategies and risk mitigation plans to ensure continuity and scalability of supply
  • Lead and execute supplier qualification activities including Supplier pFMEA, process validations, inspection reports, Gage R&R, and process capability analysis
  • Select appropriate manufacturing processes and suppliers considering long-term fit, quality, capacity, and total cost of ownership
  • Collaborate with design and manufacturing teams to provide DFM feedback and ensure manufacturability and compliance with quality requirements
  • Drive supplier continuous improvement initiatives focused on quality, cost reduction, capacity improvements, and risk mitigation using structured problem-solving techniques (e.g., root cause analysis, corrective and preventive actions)
  • Manage supplier changes including manufacturing process changes, equipment qualification, facility changes, and production optimization
  • Own and drive closure of supplier variances and CAPAs with thorough root cause analysis and documentation
  • Monitor and communicate supplier performance metrics, including on-time delivery and quality indicators, to internal stakeholders and suppliers
  • Participate in supplier audits, assessments, and development to ensure compliance with quality management systems and regulatory standards
  • Manage multiple concurrent projects, effectively prioritize tasks, and provide clear communication on project status to stakeholders
  • Support sustaining production by providing timely production support and addressing line issues related to supplier components
Desired Qualifications
  • Bachelor's degree in Engineering or equivalent
  • Minimum 8 years of experience in relevant field and a bachelor's degree in engineering, or equivalent combination of education and experience
  • Knowledge of medical device development and regulatory standards (e.g., FDA, ISO 13485)
  • Experience with supplier development and quality systems,
  • Experience with DRB/ECM or other supplier qualification platforms
  • Experience leading cross-functional teams in a regulated medical device environment
  • Understanding of design for manufacturability and design for assembly principles in medical devices
  • Familiarity with supplier quality agreements and regulatory requirements related to suppliers

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Simplify Jobs

Simplify's Take

What believers are saying

  • da Vinci 5 updates create software-driven upgrades and workflow monetization.
  • Ion growth expands a second engine beyond soft-tissue robotic surgery.
  • Installed base above 11,000 systems supports durable consumables and service growth.

What critics are saying

  • FDA recalls on da Vinci instruments threaten recurring revenue and surgeon trust.
  • Lower-cost robotic rivals pressure placements, pricing, and hospital contract renewals.
  • MedTech valuation compression can outpace Intuitive's earnings growth for months.

What makes Intuitive Surgical unique

  • Pioneer of robotic-assisted surgery, anchored by da Vinci and Ion platforms.
  • Global leader in minimally invasive care, serving hospitals and surgical centers.
  • Large recurring revenue base from instruments, accessories, and service contracts.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Intuitive Surgical who can refer or advise you

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 7th, 2026
Intuitive Surgical emerges as dark horse in anti-obesity market as surgery outperforms GLP-1 drugs

Intuitive Surgical could emerge as a dark horse in the anti-obesity market as bariatric surgery proves more effective than GLP-1 drugs for long-term weight loss. A recent study of over 50,000 patients found surgery patients lost an average of 58 pounds after two years, compared to just 12 pounds for those using GLP-1 medications. The study also showed surgery delivers more sustainable results. Gastric bypass patients maintain around 52% of their excess weight loss after 10 years, whilst GLP-1 users often regain all lost weight after stopping treatment. Intuitive's da Vinci surgical system offers minimally invasive bariatric surgery options. The company generated $10.1 billion in revenue last year, up from $8.4 billion, with profit margins around 28%. Despite shares falling over 20% this year, the company's position in surgical innovation makes it a compelling long-term investment.

Yahoo Finance
Mar 29th, 2026
Intuitive Surgical shares drop 19% YTD, but analysts see 15% upside potential

Intuitive Surgical has experienced recent share price weakness, declining 3% in one day with negative returns over the past week, month and three months. The stock currently trades at $452.66, down 10.1% over one month and 19.45% year-to-date, though three-year total shareholder returns remain strong at 77.19%. The medical technology company reports annual revenue of $10.1 billion and net income of $2.9 billion, maintaining a dominant position in minimally invasive surgical technology. According to one valuation analysis, Intuitive Surgical's fair value sits at $532.46, suggesting the stock is undervalued by approximately 15% at current levels. The analysis projects 12% annual revenue growth over the next five years, supported by recurring revenues from spare parts and software licences, with profit margins expected to reach 30% from the current 28.6%.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical shares up 23% after Jim Cramer's buy recommendation

Intuitive Surgical shares rose 23% following Jim Cramer's recommendation on CNBC's Squawk on the Street in June 2025, where he urged investors to "just go buy ISRG". The medical robotics company experienced a 27% surge in October after reporting third-quarter earnings that beat analyst estimates. Revenue reached $2.51 billion against expectations of $2.40 billion, whilst adjusted earnings per share hit $2.40 versus the predicted $1.98. However, the stock declined 2.7% in January 2026 after Intuitive Surgical released preliminary fourth-quarter results, citing concerns that Medicaid funding cuts and competing products could slow growth of its robotic surgical systems. Despite the recent setback, shares remain up significantly since Cramer's initial endorsement, though they're down 7.8% over the past year.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical faces tariff headwinds and rising competition despite 19% revenue growth to $2.87B

Intuitive Surgical faces headwinds from tariffs and increased competition in the robotic-assisted surgery market, yet its fundamentals remain strong. The medical device company reported fourth-quarter revenue growth of 19% to $2.87 billion, whilst adjusted earnings per share rose 14.5% to $2.53. Procedures using its da Vinci surgical system increased 17%, with the installed base growing 12% to 11,106 units. However, the stock trades at 47.6 times forward earnings, compared to the healthcare sector average of 17.1. New competition is emerging, with Medtronic's Hugo system recently cleared and Johnson & Johnson expected to launch its own device soon. Despite these challenges, Intuitive Surgical maintains advantages through switching costs and extensive real-world data, whilst the underpenetrated robotic-assisted surgery market offers long-term growth potential.

Yahoo Finance
Mar 24th, 2026
ISRG maintains 37% operating margins in Q4 despite 95 bps tariff drag

Intuitive Surgical maintained a 37% operating margin in Q4 despite tariffs creating a 95 basis point drag, alongside higher facility costs and unfavourable product mix from newer platforms like da Vinci 5 and Ion. The company offset these pressures through product cost reductions, component savings and manufacturing efficiencies. Procedure growth of 18% in Q4 and recurring revenue now comprising 81% of total revenues provided operating leverage. Management's 2026 gross margin guidance of 67-68% suggests continued stability, even as tariff headwinds are expected to increase to roughly 1.2% of revenues. Meanwhile, Boston Scientific expanded adjusted operating margins by 100 basis points to 28% in 2025, though tariffs will offset favourable product mix in 2026. The company expects 50-75 basis points operating margin expansion in 2026 through scale efficiencies and supply-chain optimisation.

INACTIVE